image
Healthcare - Medical - Healthcare Information Services - NASDAQ - US
$ 20.46
-2.8 %
$ 1.5 B
Market Cap
-7.78
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one SDGR stock under the worst case scenario is HIDDEN Compared to the current market price of 20.5 USD, Schrödinger, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one SDGR stock under the base case scenario is HIDDEN Compared to the current market price of 20.5 USD, Schrödinger, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one SDGR stock under the best case scenario is HIDDEN Compared to the current market price of 20.5 USD, Schrödinger, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart SDGR

image
$27.0$27.0$26.0$26.0$25.0$25.0$24.0$24.0$23.0$23.0$22.0$22.0$21.0$21.0$20.0$20.0$19.0$19.0$18.0$18.0$17.0$17.0Jan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 Jun
FINANCIALS
208 M REVENUE
-4.21%
-209 M OPERATING INCOME
-17.95%
-187 M NET INCOME
-459.54%
-157 M OPERATING CASH FLOW
-15.09%
149 M INVESTING CASH FLOW
-22.90%
10.1 M FINANCING CASH FLOW
11.88%
59.6 M REVENUE
-32.57%
-50.9 M OPERATING INCOME
-145.70%
-59.8 M NET INCOME
-48.72%
144 M OPERATING CASH FLOW
563.03%
30.6 M INVESTING CASH FLOW
30.49%
409 K FINANCING CASH FLOW
243.70%
Balance Sheet Schrödinger, Inc.
image
Current Assets 635 M
Cash & Short-Term Investments 352 M
Receivables 255 M
Other Current Assets 27.5 M
Non-Current Assets 188 M
Long-Term Investments 43.2 M
PP&E 136 M
Other Non-Current Assets 8.95 M
42.77 %31.02 %3.34 %5.25 %16.53 %Total Assets$823.2m
Current Liabilities 192 M
Accounts Payable 10.7 M
Short-Term Debt 16.8 M
Other Current Liabilities 164 M
Non-Current Liabilities 210 M
Long-Term Debt 101 M
Other Non-Current Liabilities 109 M
4.17 %40.90 %25.16 %27.12 %Total Liabilities$401.8m
EFFICIENCY
Earnings Waterfall Schrödinger, Inc.
image
Revenue 208 M
Cost Of Revenue 75.5 M
Gross Profit 132 M
Operating Expenses 341 M
Operating Income -209 M
Other Expenses -22.2 M
Net Income -187 M
250m250m200m200m150m150m100m100m50m50m00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)(250m)(250m)208m(75m)132m(341m)(209m)22m(187m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
63.64% GROSS MARGIN
63.64%
-100.85% OPERATING MARGIN
-100.85%
-90.16% NET MARGIN
-90.16%
-44.40% ROE
-44.40%
-22.73% ROA
-22.73%
-32.53% ROIC
-32.53%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Schrödinger, Inc.
image
20m20m00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)(140m)(140m)(160m)(160m)(180m)(180m)2018201820192019202020202021202120222022202320232024202420252025
Net Income -187 M
Depreciation & Amortization 6.16 M
Capital Expenditures -7.31 M
Stock-Based Compensation 49.9 M
Change in Working Capital -13 M
Others 150 M
Free Cash Flow -165 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Schrödinger, Inc.
image
Wall Street analysts predict an average 1-year price target for SDGR of $28.5 , with forecasts ranging from a low of $27 to a high of $30 .
SDGR Lowest Price Target Wall Street Target
27 USD 31.96%
SDGR Average Price Target Wall Street Target
28.5 USD 39.30%
SDGR Highest Price Target Wall Street Target
30 USD 46.63%
Price
Max Price Target
Min Price Target
Average Price Target
30302828262624242222202018181616Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 9
6. Ownership
Insider Ownership Schrödinger, Inc.
image
Sold
0-3 MONTHS
420 K USD 1
3-6 MONTHS
340 K USD 5
6-9 MONTHS
27.2 K USD 1
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Schrödinger, Inc. (“Schrödinger” or the “Company”) (NASDAQ: SDGR).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. globenewswire.com - 4 days ago
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on June 13, 2025, the company granted restricted stock units (RSUs) with respect to 10,290 shares of the company's common stock to five newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company's board of directors, and were made as a material inducement t. businesswire.com - 5 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR NEW YORK CITY, NY / ACCESS Newswire / June 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Schrödinger, Inc.("Schrödinger" or the "Company") (NASDAQ:SDGR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com - 6 days ago
Schrödinger: Assessing The Signal And The Noise In The Phase 1 Results Schrödinger's SGR-1505 Phase 1 data shows encouraging safety and niche efficacy, especially in BTKi-resistant Waldenström macroglobulinemia patients. Despite a headline 22% ORR, the nuanced data supports continued development, though competition and high efficacy benchmarks in B-cell malignancies remain challenges. Financially, Schrödinger's software business is growing steadily, with strong cash reserves and manageable risks, supporting ongoing R&D investment. seekingalpha.com - 1 week ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR NEW YORK CITY, NY / ACCESS Newswire / June 13, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Schrödinger, Inc.("Schrödinger" or the "Company") (NASDAQ:SDGR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com - 1 week ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR NEW YORK , June 12, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Schrödinger, Inc. ("Schrödinger" or the "Company") (NASDAQ: SDGR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. prnewswire.com - 1 week ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR NEW YORK CITY, NY / ACCESS Newswire / June 11, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Schrödinger, Inc.("Schrödinger" or the "Company") (NASDAQ:SDGR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com - 1 week ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Schrödinger, Inc. (“Schrödinger” or the “Company”) (NASDAQ: SDGR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. globenewswire.com - 1 week ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR NEW YORK, NY / ACCESS Newswire / June 9, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Schrödinger, Inc.("Schrödinger" or the "Company") (NASDAQ:SDGR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com - 1 week ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR NEW YORK , June 7, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Schrödinger, Inc. ("Schrödinger" or the "Company") (NASDAQ: SDGR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. prnewswire.com - 2 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Schrödinger, Inc. (“Schrödinger” or the “Company”) (NASDAQ: SDGR).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. globenewswire.com - 2 weeks ago
Bronstein, Gewirtz & Grossman, LLC Encourages Schrödinger, Inc. (SDGR) Shareholders to Inquire about Securities Investigation NEW YORK, NY / ACCESS Newswire / June 6, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Schrödinger, Inc. ("Schrödinger" or "the Company") (NASDAQ:SDGR). Investors who purchased Schrödinger securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SDGR. accessnewswire.com - 2 weeks ago
8. Profile Summary

Schrödinger, Inc. SDGR

image
COUNTRY US
INDUSTRY Medical - Healthcare Information Services
MARKET CAP $ 1.5 B
Dividend Yield 0.00%
Description Schrödinger, Inc., together with its subsidiaries, provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
Contact 1540 Broadway, New York City, NY, 10036 https://www.schrodinger.com
IPO Date Feb. 6, 2020
Employees 891
Officers Ms. Yvonne Tran Esq. Corporate Secretary, Chief Legal & People Officer Dr. Geoffrey Craig Porges MBBS Executive Vice President & Chief Financial Officer Mr. Kenneth Patrick Lorton Executive Vice President, Chief Technology Officer & Chief Operating Officer of Software Dr. Karen Akinsanya Ph.D. President of Research & Development Therapeutics Prof. William Goddard III Co-Founder & Scientific Advisor Dr. Richard A. Friesner Ph.D. Co-Founder, Scientific Advisory Chairman and Director Dr. Robert Lorne Abel Ph.D. Executive Vice President, Chief Scientific Officer of Platform and Head of Modeling R&D Mr. Shane Brauner Executive Vice President & Chief Information Officer Dr. Ramy Farid Ph.D. Chief Executive Officer, President & Director Ms. Jaren Irene Madden Senior Vice President of Investor Relations & Corporate Affairs